Pathological roles of α-synuclein in neurological disorders

The Lancet Neurology

Volumn 10, Issue 11, 2011, Pages 1015-1025

  Vekrellis, Kostas ^a   Xilouri, Maria ^a   Emmanouilidou, Evangelia ^a   Rideout, Hardy J ^a   Stefanis, Leonidas ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN;

AUTOPHAGY; CALCIUM HOMEOSTASIS; CYTOSKELETON; DISEASE COURSE; GENE MUTATION; GENETIC DISORDER; HUMAN; LYSOSOME; NEUROTRANSMITTER RELEASE; OLIGOMERIZATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; PROTEIN SECRETION; REVIEW; SYNAPSE;

ALPHA-SYNUCLEIN; BRAIN; HUMANS; LEWY BODIES; LEWY BODY DISEASE; NEURONS; PARKINSON DISEASE;

EID: 80054755695     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70213-7     Document Type: Review

References (124)

1. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:11282-11286.
2. Vekrellis K, Rideout HJ, Stefanis L Neurobiology of α-synuclein. Mol Neurobiol 2004, 30:1-21.
3. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
4. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
5. Larsen KE, Schmitz Y, Troyer MD, et al. α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006, 26:11915-11922.
6. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 2005, 123:383-396.
7. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009, 19:254-265.
8. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649. International Parkinson Disease Genomics Consortium.
9. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009, 65:610-614.
10. Kahle PJ α-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115:87-95.
11. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
12. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001, 32:213-223.
13. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007, 27:3338-3346.
14. Trojanowski JQ, Lee VM Aggregation of neurofilament and α-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998, 55:151-152.
15. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000, 97:571-576.
16. Karpinar DP, Balija MB, Kugler S, et al. Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models. EMBO J 2009, 28:3256-3268.
17. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011, 108:4194-4199.
18. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-α-synuclein adduct. Science 2001, 294:1346-1349.
19. Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ Dopamine promotes formation and secretion of non-fibrillar α-synuclein oligomers. Exp Mol Med 2011, 43:216-222.
20. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296:661-670.
21. Chiba-Falek O, Touchman JW, Nussbaum RL Functional analysis of intra-allelic variation at NACP-Rep1 in the α-synuclein gene. Hum Genet 2003, 113:426-431.
22. Cronin KD, Ge D, Manninger P, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain. Hum Mol Genet 2009, 18:3274-3285.
23. Linnertz C, Saucier L, Ge D, et al. Genetic regulation of α-synuclein mRNA expression in various human brain tissues. PLoS One 2009, 4:e7480.
24. Clough RL, Stefanis L A novel pathway for transcriptional regulation of α-synuclein. FASEB J 2007, 21:596-607.
25. Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein. Proc Natl Acad Sci USA 2008, 105:10907-10912.
26. Clough RL, Dermentzaki G, Stefanis L Functional dissection of the α-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J Neurochem 2009, 110:1479-1490.
27. Paillusson S, Tasselli M, Lebouvier T, et al. α-Synuclein expression is induced by depolarization and cyclic AMP in enteric neurons. J Neurochem 2010, 115:694-706.
28. Jowaed A, Schmitt I, Kaut O, Wullner U Methylation regulates α-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010, 30:6355-6359.
29. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM Repression of α-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 2009, 106:13052-13057.
30. Doxakis E Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153. J Biol Chem 2010, 285:12726-12734.
31. Cuervo AM, Wong ES, Martinez-Vicente M Protein degradation, aggregation, and misfolding. Mov Disord 2010, 25(suppl 1):S49-S54.
32. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003, 278:25009-25013.
33. Emmanouilidou E, Stefanis L, Vekrellis K Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging 2008, 31:953-968.
34. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
35. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008, 283:23542-23556.
36. Lee HJ, Khoshaghideh F, Patel S, Lee SJ Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004, 24:1888-1896.
37. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010, 67:1464-1472.
38. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA Lysosomal degradation of α-synuclein in vivo. J Biol Chem 2010, 285:13621-13629.
39. Iwata A, Maruyama M, Akagi T, et al. α-Synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 2003, 12:2625-2635.
40. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L Abberrant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009, 4:e5515.
41. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008, 118:777-788.
42. Yang Q, She H, Gearing M, et al. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009, 323:124-127.
43. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001, 21:9549-9560.
44. Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of α-synucleinopathy. PLoS One 2010, 5:e9313.
45. Hsu LJ, Sagara Y, Arroyo A, et al. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000, 157:401-410.
46. Yu WH, Dorado B, Figueroa HY, et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009, 175:736-747.
47. Spencer B, Potkar R, Trejo M, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 2009, 29:13578-13588.
48. Winslow AR, Chen CW, Corrochano S, et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 2010, 190:1023-1037.
49. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
50. Cullen V, Sardi SP, Ng J, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 2011, 69:940-953.
51. Manning-Bog AB, Schule B, Langston JW α-Synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009, 30:1127-1132.
52. Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 2011, 102:436-447.
53. Yap TL, Gruschus JM, Velayati A, et al. α-Synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 2011, 286:28080-28088.
54. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
55. Cooper AA, Gitler AD, Cashikar A, et al. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
56. Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 2011, 108:12101-12106.
57. Li WW, Yang R, Guo JC, et al. Localization of α-synuclein to mitochondria within midbrain of mice. Neuroreport 2007, 18:1543-1576.
58. Zhang L, Zhang C, Zhu Y, et al. Semi-quantitative analysis of α-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res 2008, 1244:40-52.
59. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α-synuclein. J Biol Chem 2011, 286:20710-20726.
60. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008, 283:9089-9100.
61. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006, 26:41-50.
62. Kamp F, Exner N, Lutz AK, et al. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 2010, 29:3571-3589.
63. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet 2007, 16:2377-2393.
64. Liu G, Zhang C, Yin J, et al. α-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett 2009, 454:187-192.
65. Loeb V, Yakunin E, Saada A, Sharon R The transgenic overexpression of α-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem 2010, 285:7334-7343.
66. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010, 486:235-239.
67. Betarbet R, Canet-Aviles RM, Sherer TB, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006, 22:404-420.
68. Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53T α-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011, 286:10814-10824.
69. Fournier M, Vitte J, Garrigue J, et al. Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One 2009, 4:e6629.
70. Chen L, Jin J, Davis J, et al. Oligomeric α-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun 2007, 356:548-553.
71. Lee HJ, Khoshaghideh F, Lee S, Lee SJ Impairment of microtubule-dependent trafficking by overexpression of α-synuclein. Eur J Neurosci 2006, 24:3153-3162.
72. Kim M, Jung W, Lee IH, Bhak G, Paik SR, Hahn JS Impairment of microtubule system increases alpha-synuclein aggregation and toxicity. Biochem Biophys Res Commun 2008, 365:628-635.
73. Alim MA, Hossain MS, Arima K, et al. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 2002, 277:2112-2117.
74. Nakayama K, Suzuki Y, Yazawa I Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy. Am J Pathol 2009, 174:1471-1480.
75. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R α-Synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 1999, 274:25481-25489.
76. Qureshi HY, Paudel HK Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem 2011, 286:5055-5068.
77. Haggerty T, Credle J, Rodriguez O, et al. Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci 2011, 33:1598-1610.
78. Jaleel M, Nichols RJ, Deak M, et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007, 405:307-317.
79. Gillardon F Leucine-rich repeat kinase 2 phosphorylates brain tubulin-β isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration?. J Neurochem 2009, 110:1514-1522.
80. Zach S, Felk S, Gillardon F Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS One 2010, 5:e13191.
81. Lin CH, Tsai PI, Wu RM, Chien CT LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J Neurosci 2010, 30:13138-13149.
82. Melrose HL, Dachsel JC, Behrouz B, et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010, 40:503-517.
83. Muntane G, Dalfo E, Martinez A, Ferrer I Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 2008, 152:913-923.
84. Rajput A, Dickson DW, Robinson CA, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67:1506-1508.
85. Lin X, Parisiadou L, Gu XL, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
86. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
87. Kramer ML, Schulz-Schaeffer WJ Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007, 27:1405-1410.
88. Nemani VM, Lu W, Berge V, et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
89. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J Neurosci 2010, 30:8083-8095.
90. Garcia-Reitbock P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 2010, 133:2032-2044.
91. Darios F, Ruiperez V, Lopez I, Villanueva J, Gutierrez LM, Davletov B α-Synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep 2010, 11:528-533.
92. Al-Wandi A, Ninkina N, Millership S, Williamson SJ, Jones PA, Buchman VL Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging 2008, 31:796-804.
93. Greten-Harrison B, Polydoro M, Morimoto-Tomita M, et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA 2010, 107:19573-19578.
94. Lashuel HA, Petre BM, Wall J, et al. α-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002, 322:1089-1102.
95. Volles MJ, Lee SJ, Rochet JC, et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001, 40:7812-7819.
96. Danzer KM, Haasen D, Karow AR, et al. Different species of α-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007, 27:9220-9232.
97. Kostka M, Hogen T, Danzer KM, et al. Single particle characterization of iron-induced pore-forming α-synuclein oligomers. J Biol Chem 2008, 283:10992-11003.
98. Tsigelny IF, Bar-On P, Sharikov Y, et al. Dynamics of α-synuclein aggregation and inhibition of pore-like oligomer development by β-synuclein. FEBS J 2007, 274:1862-1877.
99. Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279:46363-46366.
100. 2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 2009, 111:1192-1201.
101. Huls S, Hogen T, Vassallo N, et al. AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced alpha-synuclein oligomers. J Neurochem 2011, 117:868-878.
102. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
103. Chan CS, Gertler TS, Surmeier DJ Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci 2009, 32:249-256.
104. Guzman JN, Sanchez-Padilla J, Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
105. Mosharov EV, Staal RG, Bove J, et al. α-Synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 2006, 26:9304-9311.
106. Mishizen-Eberz AJ, Norris EH, Giasson BI, et al. Cleavage of α-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 2005, 44:7818-7829.
107. Borghi R, Marchese R, Negro A, et al. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000, 287:65-67.
108. El-Agnaf OM, Salem SA, Paleologou KE, et al. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003, 17:1945-1947.
109. Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010, 30:6838-6851.
110. Sung JY, Park SM, Lee CH, et al. Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases. J Biol Chem 2005, 280:25216-25224.
111. Danzer KM, Ruf WP, Putcha P, et al. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2010, 25:326-336.
112. Lee HJ, Patel S, Lee SJ Intravesicular localization and exocytosis of α-synuclein and its aggregates. J Neurosci 2005, 25:6016-6024.
113. Simons M, Raposo G Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009, 21:575-581.
114. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008, 14:504-506.
115. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008, 14:50103.
116. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci USA 2009, 106:13010-13015.
117. Hansen C, Angot E, Bergstrom AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011, 121:715-725.
118. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int J Biochem Cell Biol 2008, 40:1835-1849.
119. Luk KC, Song C, O'Brien P, et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA 2009, 106:20051-20056.
120. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010, 5:e8762.
121. Lee EJ, Woo MS, Moon PG, et al. α-Synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010, 185:615-623.
122. Zhang W, Dallas S, Zhang D, et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant α-synuclein. Glia 2007, 55:1178-1188.
123. Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010, 285:9262-9272.
124. Emmanouilidou E, Elenis D, Papasilekas T, et al. Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS One 2011, 6:e22225.